ARTICLE | Distillery Therapeutics

Endocrine / Metabolic

October 20, 2016 7:00 AM UTC

In vitro and mouse studies suggest a UCN2-based gene therapy could help treat Type II diabetes. In a mouse model of Type II diabetes, a single IV injection of an adeno-associated viral (AAV) serotype 8 (AAV8) vector encoding UCN2 decreased blood glucose levels and increased glucose tolerance and insulin sensitivity for up to 18 weeks compared with vehicle. Next steps include testing the gene therapy in non-human primates...